Incidence of second hip fracture and compliant use of bisphosphonate
- 886 Downloads
We determined the incidence of second hip fracture and evaluated whether compliant users of bisphosphonate had a lower incidence of second hip fracture after prior hip fracture.
Bisphosphonate has been used to prevent osteoporotic fracture and is recommended for the secondary prevention after hip fracture. However, little is known regarding secondary prevention after first hip fracture. Our purpose was to determine the incidence of second hip fracture and to evaluate whether compliant use of bisphosphonate can reduce the risk of second hip fracture.
Eight hundred twenty-six patients who sustained the first hip fracture from May 2003 to October 2011 were retrospectively evaluated. The incidence of second hip fracture was compared between compliant users of bisphosphonate and nonusers.
Seventy-one (8.6 %) patients suffered a second hip fracture at mean 30.0 months (SD 24.6, range 1 to 90 months) after the initial hip fracture. The cumulative incidence of second hip fracture was 5.1 % (42/826) at 2 years and 8.6 % (71/826) at 8 years. The incidence of second hip fracture was 4.2 % (12/283) in compliant users and 10.9 % (59/543) in nonusers (p = 0.001).
Compliant use of bisphosphonate is effective in the prevention of second hip fractures.
KeywordsBisphosphonate Compliance Hip fracture Second hip fracture
Conflicts of interest
- 9.Melton LJ, 3rd, Ilstrup DM, Beckenbaugh RD, Riggs BL (1982) Hip fracture recurrence. A population-based study. Clin Orthop Relat Res 167:131–138Google Scholar
- 16.National Osteoporosis Foundation. Physician’s guide to prevention and treatment of osteoporosis. http://www.nof.org/physguide/. Accessed 15 Feb 2006
- 18.Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM (2010) American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract 16(6):1016–1019Google Scholar
- 25.Soong YK, Tsai KS, Huang HY, Yang RS, Chen JF, Wu PC, Huang KE (2012) Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int. doi: 10.1007/s00198-012-1984-z
- 28.Koval KJ, Aharonoff GB, Rosenberg AD, Bernstein RL, Zuckerman JD (1998) Functional outcome after hip fracture. Effect of general versus regional anesthesia. Clin Orthop Relat Res 348:37–41Google Scholar
- 30.McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22:2083–2098PubMedCrossRefGoogle Scholar
- 36.Souder CD, Brennan ML, Brennan KL, Song J, Williams J, Chaput C (2012) The rate of contralateral proximal femoral fracture following closed reduction and percutaneous pinning compared with arthroplasty for the treatment of femoral neck fractures. J Bone Joint Surg Am 94:418–425PubMedCrossRefGoogle Scholar
- 45.Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, Yanagimoto K, Sakota K (2007) Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 25:302–309PubMedCrossRefGoogle Scholar